Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha
| Autor: | Murat Akyol, Ahmet Alacacioglu, Ahmet Dirican, Mehmet Koseoglu, Alper Can, Yuksel Kucukzeybek, Mustafa Oktay Tarhan, Lutfiye Demir, Yasar Yildiz, Isil Somali, Ibrahim Vedat Bayoglu, Kadriye Bahriye Payzin, Cigdem Erten |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Indoles Neutrophils Epidemiology medicine.drug_class Alpha interferon Angiogenesis Inhibitors Neutropenia urologic and male genital diseases Antiviral Agents Gastroenterology Tyrosine-kinase inhibitor Renal cell carcinoma Internal medicine Biomarkers Tumor Sunitinib medicine Humans Pyrroles Lymphocytes Neoplasm Metastasis Mean platelet volume Carcinoma Renal Cell Aged Neoplasm Staging Retrospective Studies Hematologic Tests business.industry Public Health Environmental and Occupational Health Interferon-alpha Cancer Middle Aged Sunitinib malate Prognosis medicine.disease Kidney Neoplasms Survival Rate Oncology Female business Follow-Up Studies medicine.drug |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 14:2101-2105 |
| ISSN: | 1513-7368 |
| DOI: | 10.7314/apjcp.2013.14.3.2101 |
| Popis: | Background: Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as a second line treatment in metastatic renal cell carcinoma (mRCC) are limited. Prognostic and predictive value of peripheral blood markers has been shown for many cancers. Materials and Methods: Efficacy and safety profiles of sunitinib after interferon alpha (IFN-α) were evaluated based on retrospective data for 23 patients with mRCC. Hematological parameters (neutrophils, lymphocytes, platelets, mean platelet volume, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio) were recorded at the time of metastasis. It was evaluated whether hematological parameters were prognostic and predictive factors. Results: Median progression-free survival (PFS) time was 16.5 months (95%CI: 0-34.5). Median overall survival (OS) time was 25.7 months (95%CI: 10.8-40.0). Most common side effects were neutropenia (52.2%), stomatitis (26.1%) and hand-food syndrome (26.1%). PFS was found 3.13 vs 17.1 months in patients with neutrophil / lymphocyte ratio (NLR)>3 vs NLR≤3 (p:0.012). Median OS was 6.96 vs 27.1 months in patients with NLR>3 vs NLR≤3 (p:0.001).While 75% of patients who responded to sunitinib had NLR≤3, in 72% of patients with no response to sunitinib NLR>3 was detected (p:0.036). The association between the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria and NLR was statistically significant (p:0.022). Conclusions: Data on second line sunitinib treatment following cytokine in mRCC are limited. In our study, we observed second line sunitinib treatment following IFN-α to be effective and tolerable. NLRappeared to have prognostic and predictive value. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|